Compare BUDA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUDA | BMEA |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 39 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 91.1M |
| IPO Year | N/A | 2021 |
| Metric | BUDA | BMEA |
|---|---|---|
| Price | $7.78 | $1.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $9.83 |
| AVG Volume (30 Days) | 21.5K | ★ 696.3K |
| Earning Date | 03-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $0.87 |
| 52 Week High | $12.00 | $2.99 |
| Indicator | BUDA | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 36.91 |
| Support Level | $8.05 | $1.05 |
| Resistance Level | $10.42 | $1.44 |
| Average True Range (ATR) | 0.64 | 0.06 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 25.71 | 5.56 |
Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.